Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.kwalitypharma.com | |
Market Cap | 387.40 Cr. | |
Enterprise Value(EV) | 471.66 Cr. | 2023-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 10.97 | Trailing Twelve Months Ending 2023-09 |
Price-Earning Ratio (PE) | 34.04 | Trailing Twelve Months Ending 2023-09 |
Industry PE | 38.52 | Trailing Twelve Months Ending 2023-09 |
Book Value / Share | 203.60 | Trailing Twelve Months Ending 2023-09 |
Price to Book Value | 1.83 | Calculated using Price: 373.35 |
Dividend Yield | 0.00 | Period Ending 2023-03 |
No. of Shares Subscribed | 1.04 Cr. | 10,376,198 Shares |
FaceValue | 10 | |
About Kwality Pharmaceuticals Ltd. | ||
The company ‘Kwality Pharmaceuticals Limited' was incorporated on May 04, 1983 vide Certificate of Incorporation issued by the Registrar of Companies, Punjab, H.P. and Chandigarh. It is engaged in the business of manufacturing of broad range of finished pharmaceutical formulations in a dosage form. It carries out its production through state-of-the-art manufacturing units situated at 6th Mile Stone, Village Nag Kalan, Majitha Road, Amritsar - 143006, Punjab, which is also its registered/administrative office and another manufacturing facility situated at 1-A Industrial Area, Raja ka bagh, Jassur, Himachal Pradesh. Both of its manufacturing facilities are well equipped and multiple products are manufactured at these facilities. Since incorporation, the company is ever progressing in Domestic and International market based on its commitment towards high quality and timely supplies. It provides specified and quality products for its customers while maintaining honesty, integrity and loyalty to its employees and customers. |
1 Day |
|
+0.55% |
1 Week |
|
-3.52% |
1 Month |
|
+9.48% |
3 Month |
|
-5.23% |
6 Month |
|
+24.52% |
1 Year |
|
+12.94% |
2 Year |
|
-62.63% |
5 Year |
|
+555.54% |
10 Year |
|
9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
Return on Equity (%) | 4.43 | 6.54 | 14.41 | 16.51 | 23.13 | 20.10 | 28.21 | 99.66 | 10.15 | |
Return on Capital Employed (%) | 9.58 | 12.34 | 19.64 | 19.19 | 21.91 | 18.49 | 26.36 | 95.32 | 12.06 | |
Return on Assets (%) | 2.21 | 2.90 | 5.37 | 5.29 | 7.50 | 6.90 | 9.97 | 47.33 | 5.55 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
Shh. Funds | 19 | 22 | 26 | 30 | 37 | 46 | 61 | 181 | 201 | 212 | |
Non Curr. Liab. | 1 | 3 | 4 | 5 | 8 | 20 | 28 | 21 | 29 | 25 | |
Curr. Liab. | 17 | 27 | 42 | 62 | 61 | 68 | 78 | 139 | 126 | 119 | |
Minority Int. | 0 | 0 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | |
Equity & Liab. | 37 | 51 | 71 | 96 | 105 | 132 | 166 | 341 | 354 | 355 | |
Non Curr. Assets | 13 | 13 | 18 | 21 | 30 | 43 | 60 | 113 | 146 | 150 | |
Curr. Assets | 24 | 38 | 53 | 75 | 75 | 89 | 106 | 228 | 207 | 205 | |
Misc. Exp. not W/O | 0 | 0 | 0 | 0 | |||||||
Total Assets | 37 | 51 | 71 | 96 | 105 | 132 | 166 | 341 | 354 | 355 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09 Rs. Cr. TTM |
Net Sales | 52 | 74 | 98 | 137 | 166 | 139 | 262 | 456 | 251 | 262 | |
Other Income | 0 | 0 | 1 | 1 | 1 | 4 | 2 | 4 | 3 | 2 | |
Total Income | 53 | 75 | 100 | 138 | 167 | 143 | 264 | 460 | 254 | 265 | |
Total Expenditure | -49 | -69 | -89 | -126 | -151 | -125 | -233 | -285 | -190 | -207 | |
PBIDT | 4 | 5 | 10 | 12 | 16 | 18 | 30 | 175 | 64 | 58 | |
Interest | -1 | -1 | -2 | -2 | -2 | -3 | -3 | -3 | -7 | -8 | |
Depreciation | -1 | -2 | -3 | -3 | -3 | -4 | -6 | -11 | -15 | -18 | |
Taxation | -1 | -1 | -2 | -3 | -3 | -3 | -6 | -42 | -6 | -4 | |
Exceptional Items | -17 | -17 | |||||||||
PAT | 1 | 1 | 3 | 4 | 8 | 8 | 15 | 120 | 19 | 11 | |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
Share Associate | |||||||||||
Other Related Items | |||||||||||
Consolidated Net Profit | 1 | 2 | 3 | 5 | 8 | 8 | 15 | 120 | 19 | 11 | |
Adjusted EPS | 1 | 2 | 3 | 4 | 7 | 8 | 15 | 116 | 19 | 11 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Cash Fr. Operatn. | -1 | 1 | -3 | 4 | -1 | 14 | 6 | 27 | 61 | 41 | |
Cash Fr. Inv. | -3 | -1 | -2 | -7 | -6 | -12 | -18 | -23 | -63 | -48 | |
Cash Fr. Finan. | 3 | 1 | 6 | 5 | 5 | -2 | 12 | 1 | 6 | 1 | |
Net Change | -1 | 1 | 0 | 2 | -1 | 0 | 0 | 4 | 3 | -6 | |
Cash & Cash Eqvt | 1 | 1 | 1 | 3 | 2 | 1 | 2 | 6 | 9 | 3 |
Fri, 10 Nov 2023
Announcement under Regulation 30 (LODR)-Newspaper Publication NEWSPAPER PUBLICATIONS OF FINANCIAL RESULTS FOR Q.E. 30-09-2023 |
Sat, 04 Nov 2023
Disclosure Of Related Party Transactions Pursuant To Regulation 23(9) Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 (Listing Regulations') For The Half Year Ended September 30 2023 Related Party Transactions for the half year ended 30-09-2023 |
Sat, 04 Nov 2023
Board Meeting Outcome for Submission Of Unaudited Financial Results For The Quarter And Half Year Ended 30-09-2023 Pursuant to Regulation 30 & 33 read with clause 4 (h) of Para A of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015 (Listing Regulations) this is to inform your that Board of Directors in its meeting held today i.e. November 04 2023 have inter-alia considered and approved the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended on September 30 2023 along with Limited Review Report issued by Statutory Auditors of the Company. A copy of the same is enclosed herewith. |
Fri, 08 Dec 2023 |
|
|
|
|
|